BioLife Solutions Inc (BLFS) 銘柄情報

Looking for a great year in ‘24 from BLFS due to unloading the freezer line that has crippled the profitability of this equity. Instead of being a good fit, it ended up being a company that was filled with quality and supply problems. Still having a hard time figuring out why this wasn’t investigated thoroughly before pulling the trigger on buying them.

Looking forward….the future looks bright if the casting off of the freezer line is timely and not too painful.

I hope they are working on something good.

Poor quarter. Worried that management is off the rails. Bad decision to buy the Stirling Freezer line. Now costs are increasing while revenues aren’t. Couldn’t get in on the conference call. Operators kept hanging up on me when connecting me. When I was finally able to get through, it was concluded.

Rethinking my position with this equity

Can’t find any news as to why this stock took a beating yesterday. Obviously some people knew something; the volume was triple the average volume. Earnings out on Wednesday. I hope they didn’t spend like a drunken sailor at the end of a three day pass.

Great growth in all segments. Horrible losses on the quarter. Evidently bought one bad company that is sucking the profits out of the company. Not sure I have faith in the current management to continue to hold this stock. As bad as the profit and operating margins are, increased sales forecasts may make them go broke faster. What a disappointment

I don't know if others have the same thinking but the release of un-audited sales figures looks a bit amateurish in my opinion. It's a fore teller of what the sales may show in the 4th quarter and year end result....but those could change as well. It certainly didn't show plus or minus cost increases/decreases. It's moot, other than the fact that sales increased substantially in all business segments. That's a good thing.

Hopefully the company will show a profit once this all shakes out

I've waited so long here. Doesn't hurt anymore.

Great news. The market obviously liked it. Glad I own it.

Sent: Tue Aug 24 2021 6:04:55 PM EDT
BusinessWire, GlobeNewswire and PR Newswire News
BioLife Solutions Inc BLFS:NASDAQ
Bio-Techne Set to Join S&P 500; Saia, Mimecast & Option Care Health to Join S&P MidCap 400; Others to Join S&P SmallCap 600
PR Newswire
6:04 PM ET
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 effective prior to the opening of trading on Monday, August 30:

-- S&P MidCap 400 constituent Bio-Techne Corp. (NASD:TECH) will replace Maxim Integrated Products Inc. (NASD:MXIM) in the S&P 500, S&P SmallCap 600 constituent Saia Inc. (NASD:SAIA) will replace Bio-Techne in the S&P MidCap 400, and BioLife Solutions Inc. (NASD:BLFS) will replace Saia in the S&P SmallCap 600. S&P 500 constituent Analog Devices Inc. (NASD:ADI) is acquiring Maxim Integrated Products in a deal pending final conditions.

I feel much better now. But, still licking my wounds from
that last reverse split years ago.

Happy now?

I'd be nice to see a 20% rise today.

Come on BLFS...share some shareholder value. Let her rip.

Reading the quarterly report states that they expect over $83 million in the following three quarters. With all of the acquisitions, costs, mirrored management staffs creating elevated expenses, they need to get a handle on this and show operating profits. The sooner the better. If not, the stock price will be exasperating

They beat on revenues. Need to show some shareholder value.

At least above $40.

This stocks should be around $100.00 per share. My opinion only. They have monstrous revenue.

I don't see how this pullback can be anything but a huge buying opportunity.

BioLife Solutoins, Inc Is Fundamental To Cell And Gene Therapy

BioLife Solutions, Inc (NASDAQ: BLFS) is uniquely positioned in that it is a supplier of highly specialized equipment for the cell and gene therapy industries. While not a health care company itself it is fundamental to the industry and a company whose stock is on the move. Not only did the company deliver a solid 77% increase in YOY revenue but it announced a game-changing acquisition and got an important upgrade to boot.

The acquisition is Global Cooling, the parent company of Stirling Ultracold, a manufacturer of ultra-low temperature mechanical freezers. The deal is an all-stock transaction that will grow BioLife Solutions revenue by 80% by the end of the year with accretive impact to bottom-line results in 2022. The upgrade comes from Benchmark and is from Neutral to Buy. The price target is $54 or 40% from upside from Monday’s close but don’t rush to buy just yet. The premarket action has this stock up 20% so we suggest waiting for a pullback before making any decisions.

Apparently that move was easily absorbed.

Go BLFS!

Won't the offering at $14.50 be dilutive?

News: $BLFS Here's Why BioLife Solutions Jumped Higher Today

BioLi f e Solutions (NASDAQ: BLFS) , which makes products that are used in the production of cell and gene therapies, is up 11.9% at 1:55 p.m. EDT after the company announced preliminary revenue for the second quarter and used the opportunity to raise $75 million. BioLife Solutions estimat...

In case you are interested BLFS - Here's Why BioLife Solutions Jumped Higher Today

News: $BLFS BioLife Solutions Announces Pricing of $75 Million Public Offering of Common Stock

BOTHELL, Wash. , July 2, 2020 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the pricing of its public o...

Find out more BLFS - BioLife Solutions Announces Pricing of $75 Million Public Offering of Common Stock

BOTHELL, Wash., May 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced preliminary revenue for the first quarter of 2020.

Cell and gene therapy tools. (PRNewsfoto/BioLife Solutions, Inc.)
Cell and gene therapy tools. (PRNewsfoto/BioLife Solutions, Inc.)
Preliminary (unaudited) Q1 2020 Revenue

Total revenue for the first quarter of 2020 was $12.1 million, a 110% increase over the first quarter of 2019 and a 46% sequential increase over the fourth quarter of 2019. Revenue growth was driven by significantly higher demand for biopreservation media, which accounted for approximately 72% of total revenue. Sales of BioLife's ThawSTAR®, evo® and Custom Biogenic Systems® freezer products accounted for the balance of revenue and were in line with management's expectations.

Mike Rice, BioLife's CEO, remarked, "As reported by other high-value bioproduction tools suppliers across the advanced therapeutics supply chain, we experienced increased demand during the first quarter as numerous customers placed replenishment and safety stock orders to ensure their clinical development programs could continue unabated during the COVID-19 pandemic."

Withdrawal of 2020 Guidance

Due to uncertainty regarding the impact of COVID-19 on BioLife and its customers, BioLife is withdrawing financial guidance for 2020. Management will be monitoring order flow and customer forecasts throughout the year and will provide additional detail on its business and outlook during the first quarter conference call.

Q1 2020 Earnings Call Date

The Company will announce first quarter 2020 financial results after market close on Thursday, May 14, 2020 and will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 2085346. A webcast replay will be available approximately two hours after the call and will be archived on http://www.biolifesolutions.com/ for 90 days.

https://finance.yahoo.com/quote/BLFS?p=BLFS

With respect to our current outlook for 2020, we have updated the preliminary guidance we provided last November and now expect total revenue for 2020 will be between $48 million to $53 million, reflecting year-over-year growth of 75% to 94% on an as reported basis and approximately 32% on a pro forma basis. We have lowered our revenue guidance for the evo product line by $2 million to $3 million for 2020 to reflect the delays we have seen in the final validation of the technology by a large commercial cell therapy company.

We estimate that media revenue will grow between 20% to 30% and account for approximately 55% of total 2020 revenue. With CBS freezer line accounting for another 35% and the evo and thaw product lines, each contributing approximately 5% of revenue. The last comment regarding revenue guidance is that we expect to see sequential revenue increases throughout the year with an estimated 40% of total 2020 revenue coming in the first half and the remaining 60% in the second half of the year.

Our adjusted gross margin for 2020 should fall between 58% to 62% given the lower margin profile of the evo and CBS product lines. However, we expect sequential increases in gross margin throughout the year as higher margin products are introduced at CBS and the benefits of leverage are realized. We expect approximately $500,000 of acquisition related inventory step up charges to increased COGS in Q1 and Q2 of this year. We expect 2020 operating expenses to be in the range of $28 million to $30 million, inclusive of $2.8 million of intangible asset amortization expense. We believe that operating expenses will remain relatively flat on a quarterly basis throughout the year.

Finally, we expect to be positive on the operating net income and EBITDA lines on a GAAP and a non-GAAP basis for the full year of 2020 and exit the year with an adjusted EBITDA margin of 20% to 25%. Finally, we currently have $20.8 million common shares issued in outstanding and a fully diluted share count of $27.5 million.

https://www.fool.com/earnings/call-transcripts/2020/03/11/biolife-solutions-inc-blfs-q4-2019-earnings-call-t.aspx

BioLife Solutions Announces Third Quarter 2019 Financial Results

https://finance.yahoo.com/news/biolife-solutions-announces-third-quarter-210100681.html

" EBITDA, a non-GAAP measurement, for the nine months ended September 30, 2019 was $11.0 million compared with $2.5 million for the prior-year period. Adjusted EBITDA for the nine months ended September 30, 2019 was $4.3 million compared with $4.0 million for the first nine months of 2018.

Roderick de Greef, BioLife Chief Financial Officer, remarked, "With the addition of CBS following the acquisitions of SAVSU and Astero earlier this year, along with expectation for continued growth in our cell and gene therapy franchise, our 2020 outlook is for revenue to increase by 69% to 90% compared with the midpoint of our revised 2019 revenue guidance."

2019 Financial Guidance

Management updated 2019 financial guidance to include contributions from Astero (beginning April 1), SAVSU (beginning August 8) and CBS (beginning November 12), as follows:

Total revenue is now expected to be $27.5 million to $31.5 million, representing growth of 39% to 60% over 2018; this compares with previous guidance for 2019 total revenue to be $27.5 million to $30.5 million. The acquisition of CBS is expected to contribute $1.0 million to $2.0 million in revenue for the remainder of 2019, offset by a reduction of $1.0 million in media revenue reflecting the order shortfall in the third quarter."

BioLife Solutions Acquires Custom Biogenic Systems

"BOTHELL, Wash., Nov. 12, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the acquisition of substantially all of the assets of Custom Biogenic Systems, Inc. ("CBS"). CBS, a privately held company with operations located near Detroit, is a global leader in the design and manufacture of state-of-the-art liquid nitrogen laboratory freezers and cryogenic equipment. CBS also offers a related cloud-based monitoring system that continuously assesses biologic sample storage conditions and alerts equipment owners if a fault condition occurs. Revenue for 2019 is expected to be $10 million to $11 million."

...

"With the addition of CBS, the full-year impact of the Astero Bio and SAVSU acquisitions, and continued media revenue growth, we believe 2020 revenue will be between $50 million and $56 million, or 69% to 90% growth over the midpoint of our 2019 guidance. We will provide additional 2020 financial guidance during our 2019 fourth quarter and full year conference call planned for March of next year."

https://finance.yahoo.com/news/biolife-solutions-acquires-custom-biogenic-210300913.html

With all the good news so far, we should already be at $100.00 a share. Just my opinion.

It looks like it is trying to break out here. I expect the $24 price target that was forecast by one of the investment firms to be hit.

But it may take a couple of more years before the huge breakout that I think this one is capable of. They need to have their customers start having their procedures approved which will create the big demand for product.

But that's just my take based on what management has been saying.

We continue to get great news. Stock price should be much higher than present. "Time will tell."

BLFS Sales Team Expanded...

BioLife Solutions, Inc. (BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the hiring of two key sales executives who will assist in building and leading the worldwide sales organization. Both executives report to Jim Mathers, Vice President of Global Sales.

Marcus Schulz, Vice President, Sales, evo® Platform, is responsible for managing relationships with the leading specialty couriers serving the cell and gene therapy market to drive adoption of the evo system. He will also manage C-level relationships with strategic end-user customers. Prior to joining BioLife, Marcus served in a variety of strategic business development and executive sales leadership roles with companies including Siemens Healthcare, Johnson & Johnson, Abbott Laboratories and most recently, GE Healthcare, where he managed a $1 billion annual revenue strategic account.

Andrew Sabatier, Director of Sales, North America, is responsible for managing the North American sales team, which is promoting the entire product portfolio. Prior to joining BioLife, Andrew spent the last twenty years building and leading sales teams, including at Biosafe Group, where he drove revenue from zero to nearly $30 million prior to the acquisition of Biosafe by GE Healthcare.

Mike Rice, BioLife Solutions CEO, remarked, "Marcus and Andrew bring a wealth of C-suite sales experience and demonstrable success in driving adoption of novel technologies. I look forward to them working with Jim Mathers to accelerate sales of our growing portfolio of cell and gene therapy bioproduction tools, including biopreservation media, automated thaw technologies, and evo cold chain management solutions."

https://finance.yahoo.com/news/biolife-solutions-strengthens-sales-team-120000481.html

The issue I see is that they used the same there to five years before customer protocols are approved in last November's CC. At some point that number better start shrinking.

Had the political environment impacted the speed of those approvals?

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144810645

It was another record quarter with some significant events. So why the negative reaction?

It was this segment of the earnings call indicating that it will be another three to five years before the knee of the earnings curve is hit as customer protocols are approved.

"George Zavoico -- B. Riley FBR -- Analyst

So it's really great to see always new customer always this cross-reference request for FDA master files and all that. This is mainly still for products -- industry products that are in the development, various stages of development. Everything from, I think, preclinical to registrational trial. I think the inflection point or perhaps an inflection point, of some of which you may have more than just one, will be even more of these products actually hit the market. Can you break down how many might be like in Phase 3 or preregistration -- that might predict when you might see sort of a steeper incorporation of your -- reservation product.

Michael Rice -- President and Chief Executive Officer

Sure. It's a great question. It's certainly a top of mind that. We try to analyze that through several different metrics. But, you know, nobody has the crystal ball, right, that can provide a lot of specificity. I think it's nice to say that the comments that we would make go like this. Nearly all the revenue today comes from not approved products, but from this clinical trial basket of customers. However, we have perhaps three to five additional approvals and or be late submissions that will happen in the next couple of quarters.

And we believe that the key sort of series of fresh inflection points are big step changes in the revenue are still out in the next three to five years. As you can imagine, having 10 to 20 or even 50 customers with approved therapies versus the situation that we have in the day. So we've got a wonderful growth opportunity ahead of us. And we're certainly not resting on our loyals, we continue to fill the pipeline with early stage companies. So the total universe of folks who are either currently using or intending to use our stuff in clinical trials is growing at a really rapid rate."

They will continue to acquire new customers and earnings will continue to improve, with the recent acquisition adding to the bottom line. But expect a lot of churning until revenues and earnings really begin to ramp up.

https://finance.yahoo.com/news/biolife-solutions-inc-blfs-q2-032347089.html

BioLife Solutions Announces Second Quarter 2019 Financial Results
PR Newswire
4:05 PM ET
BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today reported financial results and operational highlights for the three and six months ended June 30, 2019.

https://mma.prnewswire.com/media/464869/BioLife_Solutions.jpg

Revenue from biopreservation media and automated thaw product sales for the second quarter of 2019 reached a record of $6.7 million, an increase of 29% compared with the second quarter of 2018. For the first half of 2019 revenue totaled $1 2.5 million, representing an increase of 39% compared with the prior-year period. Product revenue growth for both periods was driven by sales of CryoStor(R) and HypoThermosol(R) biopreservation media and the recently acquired ThawSTAR(R) automated thaw products to the high-growth cell and gene therapy market.

Mike Rice, BioLife President & CEO, commented, "Throughout the second quarter, we demonstrated our ability to efficiently manage our business during a sustained period of rapid growth. Demand for our proprietary biopreservation media products continues to be strong from new and existing customers. During the quarter we received 14 new cross-reference requests for our FDA master files from cell and gene therapy companies who intend to use CryoStor and/or HypoThermosol in upcoming clinica l trials. Based on these new requests, direct customer forecasts and anticipated demand from our worldwide network of distributors, we are optimistic about how the business will perform for the balance of 2019.

"We also realized strong initial demand for automated thaw products in our first full quarter following the acquisition of Astero Bio, with 39 new customer orders. Of note, most of these customers came from the cell and gene therapy segment. We look forward to a Q4 launch of a new ThawSTAR CB automated thaw product for large volume cell and gene therapies to be frozen in cryobags. With respect to SAVSU, we remain bullish on our ability to capture a significant share of the cell and gene therapy cold chain management market. Since January 2019, the evo system has been used in initial ship ments by more than 50 cell and gene therapy companies. We look forward to integrating our sales and marketing activities and exhibiting our expanded product portfolio at 10 cell and gene therapy scientific conferences throughout the rest of the year."

Second Quarter 2019 Revenue Highlights

Cell & Gene Therapy Market Segment

-- Total product revenue: $4.0 million; representing 59% of total revenue with 33% growth over the same period last year.

-- Shipped initial orders to 51 new biopreservation media customers and 39 new automated thaw products customers, most of which were cell and gene therapy companies in the regenerative medicine market segment.

-- Received 14 new cross-reference requests for our FDA master files for CryoStor and HypoThermosol.

Worldwide Distributor Network

-- Product revenue: $2.2 million; representing 33% of total revenue with 31% growth over the same period last year.

-- Key worldwide distributors include: STEMCELL Technologies, MilliporeSigma, Thermo Fisher and VWR.

Second Quarter and Six Month 2019 Financial Results

BioLife Solutions i s presenting various financial metrics under U.S. Generally Accepted Accounting Principles (GAAP) and as adjusted (non-GAAP) to reflect acquisition-related activity. A reconciliation of GAAP to non-GAAP metrics appears at the end of this news release.

Revenue

-- Total revenue for the second quarter of 2019 increased 29% to $6.7 million compared with $5.2 million for the second quarter of 2018.

-- Sales of ThawSTAR autom ated thaw products totaled $374,000 in the second quarter.

-- Total revenue for the six months ended June 30, 2019 increased 39% to $12.5 million compared with $9.0 million for the first six months of 2018.

Gross Margin

-- Gross margin (GAAP) for the second quarter of 2019 increased to 70.8% from 70.3% in the second quarter of 2018. Adjusted gross margin (non-GAAP) for the second quarter of 2019 increased to 72.3% from 7 0.3% in 2018.

-- Gross margin (GAAP) for the six months ended June 30, 2019 increased to 71.1% from 67.7% for the same period in 2018. Adjusted gross margin (non-GAAP) for the six months ended June 30, 2019 increased to 71.9% from 67.7% in 2018.

Operating Expenses

-- Operating expenses (GAAP) for the second quarter of 2019 were $3.8 million compared with $2.4 million for the second quarter of 2018. Adjusted operating exp enses (non-GAAP) for the second quarter of 2019 were $3.7 million compared with $2.4 million in 2018.

-- Operating expenses (GAAP) for the six months ended June 30, 2019 were $7.5 million compared with $4.7 million for the same period in 2018. Adjusted operating expenses (non-GAAP) for the six months ended June 30, 2019 were $7.1 million compared with $4.7 million in 2018.

Operating Income

-- Operating income (GAAP) for the second quarter of 2019 was $919,000 compared with $1.3 million for the second quarter of 2018. Adjusted operating income (non-GAAP) for the second quarter of 2019 was $1.2 million compared with $1.3 million in 2018.

-- Operating income (GAAP) for the six months ended June 30, 2019 was $1.4 million compared with $1.4 million for the same period in 2018. Adjusted operating income (non-GAAP) for the six months ended June 30, 2019 was $1.9 million compared with $1.4 million in 2018.

Net Income Attributable to Common Stockholders

-- Net income attributable to common stockholders (GAAP) for the second quarter of 2019 was $838,000 compared with $1.0 million for the second quarter of 2018. Adjusted net income attributable to common stockholders (non-GAAP) for the second quarter of 2019 was $1.1 million compared with $1.0 million in 2018.

-- Net income attributable to common stockholders (GAAP) for the six months ended June 30, 2019 was $1.3 million compared with $943,000 for the same period in 2018. Adjusted net income attributable to common stockholders (non-GAAP) for the six months ended June 30, 2019 was $1.7 million compared with $943,000 in 2018.

Earnings per Share

-- Earnings per diluted share (GAAP) for the second quarter of 2019 were $0.03 compared with $0.05 for the second quarter of 2018. Adjusted earnings per diluted share (non-GAAP) for the second quarter of 2019 were $0.04 compared with $0.05 in 2018.

-- Earnings per diluted share (GAAP) for the six months ended June 30, 2019 were $0.05 compared with $0.05 for the same period in 2018. Adjusted earnings per diluted share (non-GAAP) for the six months ended June 30, 201 9 were $0.07 compared with $0.05 in 2018.

EBITDA

-- EBITDA, a non-GAAP measurement, for the second quarter of 2019 was $917,000 compared with $1.2 million for the second quarter of 2018. Adjusted EBITDA for the second quarter of 2019 was $1.9 million compared with $1.7 million in 2018.

-- EBITDA, a non-GAAP measurement, for the six months ended June 30, 2019 was $1.3 million compared with $1.3 million for the same period in 2018. Adjusted EBITDA for the six months ended June 30, 2019 was $3.3 million compared with $2.3 million in 2018.

Cash

-- Cash and cash equivalents as of June 30, 2019 were $19.6 million compared with $30.7 million as of December 31, 2018. The decrease reflects $12.5 million in cash consideration paid in conjunction with the acquisition of Astero Bio Corporation, which closed in early April.

Roderick de Greef, BioLif e Chief Financial Officer, remarked, "In addition to successfully integrating Astero's operations during the second quarter, our financial results at all levels remained strong."

2019 Financial Guidance

Management updated 2019 financial guidance to include contributions from Astero (beginning April 1) and SAVSU (beginning August 8), as follows:

-- Total revenue of $27.5 million to $30.5 million, representing growth of 39 % to 55% over 2018.

-- Gross margin is expected to be in a range of 69% to 70% on a GAAP and non-GAAP basis, compared with 69% in 2018.

-- Operating expenses on a GAAP basis ranging from $18.5 to $19.5 million, up from previous guidance of $15.5 to $16.5 million as a result of acquisition costs, amortization of intangible assets and the addition of SAVSU related operating expenses. Adjusted operating expenses (non-GAAP) ranging from $17 to $18 million.

-- Full-year positive adjusted operating income, adjusted net income and adjusted EBITDA.

Conference Call & Webcast

The Company will host a conference call and live webcast at 4:30 p.m. ET this afternoon. To access the live webcast, please go to www.biolifesolutions.com/earnings/. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 1368786. A webcast replay will be available approximately two hours after the call and will be archived on www.biolifesolution s.com for 90 days.

https://finance.yahoo.com/news/biolife-solutions-announces-second-quarter-200500746.html

With 18 million shares outstanding, 1 million shares to get a company that will contribute millions to the bottom line is not a lot of dilution.

This company seems to do everything right. I love that they have the complete cycle of preservation, storage, delivery and transition from storage back to viability with associated IP's.

Sorry, didn't see this morning's news release.

"BioLife Solutions Completes Acquisition of SAVSU Technologies

...

Roderick de Greef, BioLife Chief Financial Officer, stated, "We issued 1.1 million common shares to purchase the 56% of SAVSU we did not own. We expect a modest revenue contribution for the balance of 2019 of approximately $500,000. However, we believe that based on the successful conclusion of evaluations currently underway, which are expected to be finalized in the fourth quarter, the evo system product line could add $4 million to $6 million of incremental revenue in 2020"

https://finance.yahoo.com/news/biolife-solutions-completes-acquisition-savsu-120500996.html

Any thoughts about what this evening's conference call will bring?

We bought SAVSU. That is a double edge sword right now because that hits the bottom line in the short term to pave the way for the long term. How will the market react?

Any surprises?

BLFS

Earnings after the bell tomorrow. This will be important...

"Roderick de Greef, BioLife Chief Financial Officer, remarked, "We believe that owning SAVSU will allow BioLife to benefit from the high margin recurring revenue stream associated with the rental model for these products. We look forward to providing more details of thi s transaction and to revising our financial outlook during our Q2 2019 earnings call, scheduled for August 8, 2019 at 4:30 PM Eastern time.""

Only fair to post the bad with the good.

"CFO of Biolife Solutions Inc (30-Year Financial, Insider Trades) Greef Roderick De (insider trades) sold 30,000 shares of BLFS on 08/02/2019 at an average price of $18.96 a share. The total sale was $568,800."

https://finance.yahoo.com/news/biolife-solutions-inc-blfs-cfo-021503020.html

I'm not sure what to expect from this quarter's report coming up on the 8th. Plenty of good news, but it may not translate to the bottom line yet and the statements from management may indicate that it may take time for the company to realize the benefits from its investments.

Great future, but what's the short-term outlook?

BOTHELL, Wash., July 31, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's second quarter 2019 financial results will be released after market close on Thursday, August 8, 2019, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.

To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 1368786. A webcast replay will be available approximately two hours after the call and will be archived on www.biolifesolutions.com for 90 days.

https://finance.yahoo.com/news/biolife-solutions-report-second-quarter-120000966.html

BOTHELL, Wash., July 30, 2019 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies, a leading developer of advanced cold chain management tools for cell and gene therapies, and soon to be acquired by BioLife, has completed a significant expansion of its intellectual property portfolio related to protecting high value cell and gene therapies during storage and distribution.

Key attributes of new innovations by SAVSU, that are the subject of several in-process patent applications include:

An integrated system of shock absorption technologies designed to better protect fragile cell and gene therapies from in-transit damage, which can render the biologic dose useless.
Enhanced insulation and fabrication methods designed to provide dynamic thermal performance well in excess of current alternative liquid nitrogen dry vapor shippers
Predictive analytics in the evo.is cloud application designed to offer specialty couriers and other evo users with advanced notifications about the performance of the shipping containers and a dynamically updated estimation of how long the container will maintain the biologic payload at the required temperature.

Mike Rice, BioLife CEO, remarked, "The engineering team at SAVSU continues to innovate to offer best in class precision shipping containers and a state-of-the-art cloud application, both of which are being increasingly recognized and adopted by leading cell and gene therapy companies. In today's evolving "pay on cure" reimbursement environment, with payment predicated on a sustained patient response to the therapy, cell and gene therapy developers must do everything possible to mitigate the risk of delivering a non-viable dose. Competitive offerings allow for potential catastrophe, leading to therapeutic failure and economic loss. The evo cold chain management system provides an integrated solution to mitigate risks in the distribution chain."

BioLife previously announced that it had exercised its option to acquire the remaining 56% of the outstanding shares of privately held SAVSU that it currently does not own in exchange for 1.1 million shares of BioLife common stock. The acquisition will be pursuant to a share purchase agreement and is expected to close within 30 days.

https://finance.yahoo.com/news/savsu-technologies-expands-ip-portfolio-120000963.html

We probably shouldn't forget this news from before we decided to buy the whole SAVSU enchilada.

BioLife Solutions Announces SAVSU Technologies Selected by Novartis to Supply Advanced Cold Chain Management Platform for Newly Approved Gene Therapy

https://finance.yahoo.com/news/biolife-solutions-announces-savsu-technologies-120000993.html

News: $BLFS SAVSU Technologies Partners with United Cargo® to Improve Cold Chain Management and Delivery of Cell and Gene Therapies

BOTHELL, Wash. , July 23, 2019 /PRNewswire/ -- BioLife Solutions, Inc.  (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best in class bioproduction tools for cell and gene therapies, today announced that SAVSU Technologies , a leading developer of advanced cold...

Find out more SAVSU Technologies Partners with United Cargo® to Improve Cold Chain Management and Delivery of Cell and Gene Therapies

SAVSU Technologies Partners with United Cargo(R) to Improve Cold Chain Management and Delivery of Cell and Gene Therapies

https://finance.yahoo.com/news/savsu-technologies-partners-united-cargo-120000444.html

BioLife Solutions to Acquire SAVSU Technologies

8:00 AM ET
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary biopreservation media and automated cell thawing media devices for cell and gene therapies, today announced that it has exercised its option to acquire the remaining 56% of the outstanding shares of privately held SAVSU Technologies that BioLife currently does not own in exchange for 1.1 million shares of BioLife common stock. The acquisition will be pursuant to a share purchase agreement and is expected to close within 45 days.

https://mma.prnewswire.com/media/464869/BioLife_Solutions.jpg

SAVSU is the first commercial company to develop and market precision cold chain management tools specifically designed to overcome the challenges unique to commercializing cell and gene therapies. Since January 2019, through its relationships with the leading specialty couriers serving the regenerative medicine industry, SAVSU has supported more than 50 cell and gene therapy clinical trial-stage and commercial-stage companies by supplying evo precision shipping containers connected to the cloud-based evo.is real-time shipment visibility platform.

The acquisition of SAVSU is expected to further strengthen BioLife's position as a leading supplier of disruptive, enabling solutions used in the collection, manufacture, storage and distribution of cell and gene therapies. SAVSU's evo family of p recision cloud-connected shipping containers - including dry vapor liquid nitrogen, dry ice, 2 - 8oC and room temperature, all connected to the evo.is cloud-based cold chain management app - broadens BioLife's bioproduction tools portfolio and increases the Company's footprint and engagement level in its customers' cell and gene therapy manufacturing, storage and distribution workflows.

Mike Rice, BioLife President & CEO, commented, "Over the past year the SAVSU team has made significant progress in engaging with leading cell and gene therapy companies and with specialty couriers to position the evo system as a new, best-in-class alternative to providers of traditional liquid nitrogen shippers and disconnected dataloggers. SAVSU's many innovations in shipper form factor, dynamic performance , actionable data and reduction of in-transit payload damage are being recognized and highly valued by a prestigious group of cell and gene therapy developers. We welcome SAVSU to the growing family of technologies in our bioproduction tools portfolio."

The transaction includes all SAVSU intellectual property comprised of 15 pending and issued U.S. patents related to cold chain technologies. Twenty-three SAVSU employees are joining the BioLife team and will remain in the design, engineering and fabrication facility in Albuquerque, New Mexico. SAVSU also has a contract sales organization covering Europe.

SAVS U CEO Dana Barnard remarked, "We see the integration into BioLife as a natural progression in the development and growth of SAVSU. We have worked closely with BioLife since 2014 and they have been a great supporter of our mission. Today, cell and gene therapy developers face significant therapeutic and economic risks by continuing to use outdated and poor performing technologies. In the current 'pay on cure' reimbursement environment, it's very gratifying to see our innovations in cold chain management being adopted by the leaders in the regenerative medicine industry. We look forward to broadening awareness of the evo tech platform by leveraging BioLife's relationships and marketing reach."

Expected Strategic Benefits of the Transaction

-- Sales and Marketing Leverage: BioLife expects to leverage existing relationships with key decision makers among its customer base of leading cell and gene therapy companies in the regenerative medicine market. The evo platform technologies are highly advanced relative to currently marketed competitive offerings, and BioLife's expanding field-based business development and tech support team can maximize time spent with decision makers by offering a broader family of solutions.

-- Reimbursement Leverage: The reimbursement environment for expensive regenerative therapies is evolving into a "pay on cure" paradigm. With reimbursement predicated on therapeutic effic acy, cell and gene therapy companies need to mitigate the risk associated with administering a non-viable dose to the patient. Key risk mitigators include using optimized preservation media, automated thawing devices and advanced cold chain management container and information systems, all of which are now provided by BioLife.

Financial Impact

Roderick de Greef, BioLife Chief Financial Officer, remarked, "We believe that owning SAVSU will allow BioLife to benefit from the high margin recurring revenue stream associated with the rental model for these products. We look forward to providing more details of thi s transaction and to revising our financial outlook during our Q2 2019 earnings call, scheduled for August 8, 2019 at 4:30 PM Eastern time."

Hedge Funds Have Never Been This Bullish On BioLife Solutions, Inc. (BLFS)

FWIW

https://finance.yahoo.com/news/hedge-funds-never-bullish-biolife-014545155.html

Welcome to the Russell 3000, BLFS!

https://finance.yahoo.com/news/biolife-solutions-join-russell-3000-120000788.html

Looks like I may have been correct about the volatility. When markets open on Monday BLFS will be on the Russell 3000.

Is all this volatility related to the move to the Russell 3000?